Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

This study has been terminated.
(Business decision due to low subject recruitment and enrollment)
Information provided by (Responsible Party):
Regeneron Pharmaceuticals Identifier:
First received: October 26, 2009
Last updated: May 20, 2013
Last verified: May 2013

Primary objective was to demonstrate the activity of REGN475/SAR164877 in reducing the pain associated with chronic pancreatitis.

Secondary objectives were:

  • to assess the safety and tolerability of REGN475/SAR164877 in patients with chronic pancreatitis pain;
  • to characterize the pharmacokinetic, pharmacodynamic, and immunogenicity profiles of REGN475/SAR164877 in this population;
  • to measure the change in the total daily dose of rescue medications required.

Condition Intervention Phase
Abdominal Pain Upper
Drug: REGN475/SAR164877
Drug: Placebo (for REGN475/SAR164877)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of SAR164877 (REGN475) on Reduction of Pain From Chronic Pancreatitis

Resource links provided by NLM:

Further study details as provided by Regeneron Pharmaceuticals:

Primary Outcome Measures:
  • Mean change from baseline in pain intensity as assessed by Pain Intensity Numeric Rating Scale (PI-NRS) [ Time Frame: baseline and 4 weeks after injection ] [ Designated as safety issue: No ]

    The baseline value was defined as the average of PI-NRS values obtained at screening and at randomization visit.

    The Week 4 value was defined as the average of PI-NRS values obtained daily through e-Diary assessments during Week 4.

Secondary Outcome Measures:
  • Mean change from baseline in pain intensity as assessed by PI-NRS [ Time Frame: baseline and every other weeks up to 12 weeks after injection ] [ Designated as safety issue: No ]
  • Percentage of pain-free days (score "0" pain on PI-NRS) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percentage of days with rescue analgesia use [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in Short Form-12 Item Quality of Life Questionnaire [SF-12] score [ Time Frame: baseline and 4, 8, 12 weeks ] [ Designated as safety issue: No ]
  • Patient Global Impression of Change [PGIC] score [ Time Frame: 4, 8 and 12 weeks ] [ Designated as safety issue: No ]
  • Percentage of participants with at least 30% and 50% reduction from baseline in pain intensity [ Time Frame: up to 12 weeks after injection ] [ Designated as safety issue: No ]
  • Pharmacokinetic: REGN475/SAR164877 serum concentration [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 15
Study Start Date: December 2009
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: REGN475/SAR164877
REGN475/SAR164877, single injection, dose depending on the participant's body weight
Drug: REGN475/SAR164877

Pharmaceutical form: solution

Route of administration: intravenous infusion over 30 minutes

Placebo Comparator: Placebo
Placebo (for REGN475/SAR164877), single injection
Drug: Placebo (for REGN475/SAR164877)

Pharmaceutical form: solution

Route of administration: intravenous infusion over 30 minutes

Detailed Description:

The duration of the study period for each participant was up to 14 weeks, including a screening period up to 2 weeks, and 12-week follow-up after the injection.


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Moderate to severe abdominal pain due to chronic pancreatitis of at least 6 months duration.

Exclusion criteria:

  • Mild pain on the Pain Intensity-Numeric Rating Scale [PI-NRS] at screening and randomization visits;
  • Narcotic addiction;
  • Recent pancreatic surgical or endoscopic intervention for chronic pancreatitis pain;
  • Unwillingness to use study-defined rescue analgesia exclusively.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Please refer to this study by its identifier: NCT01001923

United States, California
Sanofi-Aventis Investigational Site Number 840024
Arcadia, California, United States, 91007
Sanofi-Aventis Investigational Site Number 840011
Bell Gardens, California, United States, 90201
Sanofi-Aventis Investigational Site Number 840003
Monterey, California, United States, 93940
Sanofi-Aventis Investigational Site Number 840048
San Diego, California, United States, 92103
Sanofi-Aventis Investigational Site Number 840034
Stanford, California, United States, 94305
United States, Florida
Sanofi-Aventis Investigational Site Number 840031
Miami, Florida, United States, 33144
Sanofi-Aventis Investigational Site Number 840029
St. Petersburg, Florida, United States, 33703
United States, Georgia
Sanofi-Aventis Investigational Site Number 840017
Marietta, Georgia, United States, 30060
United States, Massachusetts
Sanofi-Aventis Investigational Site Number 840013
Worcester, Massachusetts, United States, 01655
United States, New Hampshire
Sanofi-Aventis Investigational Site Number 840030
Lebanon, New Hampshire, United States, 03756
United States, New York
Sanofi-Aventis Investigational Site Number 840023
New York, New York, United States, 10016
United States, North Carolina
Sanofi-Aventis Investigational Site Number 840052
Winston Salem, North Carolina, United States, 27103
United States, Ohio
Sanofi-Aventis Investigational Site Number 840005
Cleveland, Ohio, United States, 44195
United States, Texas
Sanofi-Aventis Investigational Site Number 840043
Dallas, Texas, United States, 75204
Sanofi-Aventis Investigational Site Number 840053
Desoto, Texas, United States, 75115
Sanofi-Aventis Investigational Site Number 840050
Southlake, Texas, United States, 76092
United States, Utah
Sanofi-Aventis Investigational Site Number 840040
East Sandy, Utah, United States, 84094
Sponsors and Collaborators
Regeneron Pharmaceuticals
Study Director: Clinical Sciences & Operations Sanofi
  More Information

No publications provided

Responsible Party: Regeneron Pharmaceuticals Identifier: NCT01001923     History of Changes
Other Study ID Numbers: ACT11286
Study First Received: October 26, 2009
Last Updated: May 20, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Abdominal Pain
Pancreatitis, Chronic
Signs and Symptoms
Signs and Symptoms, Digestive
Pancreatic Diseases
Digestive System Diseases processed this record on April 16, 2014